Comparative Pharmacology
Head-to-head clinical analysis: CLOBAZAM versus SERAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOBAZAM versus SERAX.
CLOBAZAM vs SERAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clobazam is a benzodiazepine that enhances the effect of GABA at the GABA-A receptor, increasing chloride ion conductance and neuronal hyperpolarization. It has a high affinity for the α2 subunit, which may contribute to its anticonvulsant effects.
SERAX (oxazepam) is a benzodiazepine that modulates GABA-A receptors, enhancing the inhibitory effect of GABA, leading to anxiolytic, sedative, and anticonvulsant effects.
10-60 mg orally once daily, divided into two doses. Typical starting dose: 10 mg twice daily.
Oral: 5-10 mg twice daily; maximum 20 mg/day. Intravenous: 2-5 mg slow IV push, may repeat after 2 hours.
None Documented
None Documented
Clinical Note
moderateClobazam + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Clobazam."
Clinical Note
moderateClobazam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Clobazam is combined with Fluticasone propionate."
Clinical Note
moderateClobazam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Clobazam."
Clinical Note
moderateClobazam + Erythromycin
Clobazam: 36–42 hours; N-desmethylclobazam: 71–82 hours. Steady state achieved in 5–10 days.
Terminal elimination half-life is 8-15 hours (mean 12 hours) in adults; prolonged in renal impairment.
Renal: ~82% as metabolites (mainly N-desmethylclobazam and hydroxylated metabolites), unchanged clobazam <1%; fecal: ~11%.
Primarily renal (urinary) as unchanged drug (60-80%) and metabolites (20-40%); less than 5% fecal elimination.
Category C
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Erythromycin can be decreased when combined with Clobazam."